These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 32809153)
1. Towards early disease modification of Parkinson's disease: a review of lessons learned in the Alzheimer field. Smedinga M; Darweesh SKL; Bloem BR; Post B; Richard E J Neurol; 2021 Feb; 268(2):724-733. PubMed ID: 32809153 [TBL] [Abstract][Full Text] [Related]
2. Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease. de Aquino CH Front Neurol; 2021; 12():694329. PubMed ID: 34421799 [TBL] [Abstract][Full Text] [Related]
4. Prodromal Parkinson's disease: hype or hope for disease-modification trials? Mahlknecht P; Marini K; Werkmann M; Poewe W; Seppi K Transl Neurodegener; 2022 Feb; 11(1):11. PubMed ID: 35184752 [TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases. Parnetti L; Eusebi P; Lleó A Front Neurol Neurosci; 2016; 39():117-23. PubMed ID: 27463974 [TBL] [Abstract][Full Text] [Related]
6. Neuropathological correlates of parkinsonian disorders in a large Dutch autopsy series. Geut H; Hepp DH; Foncke E; Berendse HW; Rozemuller JM; Huitinga I; van de Berg WDJ Acta Neuropathol Commun; 2020 Mar; 8(1):39. PubMed ID: 32216828 [TBL] [Abstract][Full Text] [Related]
7. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology. Coskuner-Weber O; Uversky VN Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151 [TBL] [Abstract][Full Text] [Related]
8. Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies. Broadstock M; Ballard C; Corbett A Expert Opin Pharmacother; 2014 Sep; 15(13):1797-810. PubMed ID: 24992196 [TBL] [Abstract][Full Text] [Related]
10. From Prodromal to Overt Parkinson's Disease: Towards a New Definition in the Year 2040. Berg D; Postuma RB J Parkinsons Dis; 2018; 8(s1):S19-S23. PubMed ID: 30584153 [TBL] [Abstract][Full Text] [Related]
11. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Vos SJ; Verhey F; Frölich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Morbelli S; Frisoni GB; Drzezga A; Didic M; van Berckel BN; Simmons A; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Lovestone S; Muscio C; Herukka SK; Salmon E; Bastin C; Wallin A; Nordlund A; de Mendonça A; Silva D; Santana I; Lemos R; Engelborghs S; Van der Mussele S; ; Freund-Levi Y; Wallin ÅK; Hampel H; van der Flier W; Scheltens P; Visser PJ Brain; 2015 May; 138(Pt 5):1327-38. PubMed ID: 25693589 [TBL] [Abstract][Full Text] [Related]
12. Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease. Goldman JG; Aggarwal NT; Schroeder CD Neurodegener Dis Manag; 2015 Oct; 5(5):425-43. PubMed ID: 26517759 [TBL] [Abstract][Full Text] [Related]
13. The Concept of Prodromal Parkinson's Disease. Mahlknecht P; Seppi K; Poewe W J Parkinsons Dis; 2015; 5(4):681-97. PubMed ID: 26485429 [TBL] [Abstract][Full Text] [Related]
14. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease. Rijal Upadhaya A; Kosterin I; Kumar S; von Arnim CA; Yamaguchi H; Fändrich M; Walter J; Thal DR Brain; 2014 Mar; 137(Pt 3):887-903. PubMed ID: 24519982 [TBL] [Abstract][Full Text] [Related]
15. Gene therapy for Parkinson's and Alzheimer's diseases: from the bench to clinical trials. Nobre RJ; Almeida LP Curr Pharm Des; 2011; 17(31):3434-45. PubMed ID: 21902665 [TBL] [Abstract][Full Text] [Related]
16. Focus on Extracellular Vesicles: Exosomes and Their Role in Protein Trafficking and Biomarker Potential in Alzheimer's and Parkinson's Disease. Vella LJ; Hill AF; Cheng L Int J Mol Sci; 2016 Feb; 17(2):173. PubMed ID: 26861304 [TBL] [Abstract][Full Text] [Related]
18. Loss of gait control assessed by cognitive-motor dual-tasks: pros and cons in detecting people at risk of developing Alzheimer's and Parkinson's diseases. Belghali M; Chastan N; Cignetti F; Davenne D; Decker LM Geroscience; 2017 Jun; 39(3):305-329. PubMed ID: 28551877 [TBL] [Abstract][Full Text] [Related]
19. Detecting Non-cognitive Features of Prodromal Neurodegenerative Diseases. Seifan A; Ganzer CA; Ryon K; Lin M; Mahmudur R; Adolfo H; Shih C; Jacobs AR; Greenwald M; Isaacson RS Curr Aging Sci; 2019; 11(4):242-249. PubMed ID: 30845903 [TBL] [Abstract][Full Text] [Related]
20. Glycation in Parkinson's disease and Alzheimer's disease. Vicente Miranda H; El-Agnaf OM; Outeiro TF Mov Disord; 2016 Jun; 31(6):782-90. PubMed ID: 26946341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]